Table 3 Hazard ratio (95% confidence interval) for the association between tumor subtype and breast cancer-specific survival among breast cancer cases in METABRIC, overall and stratified by estrogen receptor (ER) status.

From: Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases

Tumor subtype

Overall

ER positive

ER negative

N (events)

Minimally adjusteda

Adjustedb

N (events)

Minimally adjusteda

Adjustedb

N (events)

Minimally adjusteda

Adjustedb

RNA-based TP53

Wildtype-like

764 (189)

Ref.

Ref.

734 (178)

Ref.

Ref.

23 (10)

Ref.

Ref.

Mutant-like

579 (253)

4.95 (3.47–7.06)

3.96 (2.73–5.76)

292 (125)

3.71 (2.38–5.77)

2.97 (1.88–4.68)

280 (126)

1.20 (0.44–3.24)

1.08 (0.38–3.08)

Tc

 

0.87 (0.83–0.92)

0.87 (0.83–0.91)

 

0.91 (0.86–0.97)

0.92 (0.87–0.97)

 

0.93 (0.78–1.12)

0.89 (0.73–1.08)

DNA-based TP53

Wildtype

838 (234)

Ref.

Ref.

774 (203)

Ref.

Ref.

54 (28)

Ref.

Ref.

Mutant

469 (202)

3.67 (2.61–5.15)

3.04 (2.14–4.31)

219 (95)

3.07 (1.94–4.85)

2.46 (1.54–3.91)

246 (107)

1.10 (0.58–2.08)

1.24 (0.64–2.39)

Tc

 

0.89 (0.85–0.94)

0.89 (0.85–0.93)

 

0.94 (0.89–1.00)

0.94 (0.89–1.00)

 

0.93 (0.83–1.04)

0.91 (0.82–1.02)

IHC-based TP53

Wildtype-like

600 (178)

Ref.

Ref.

504 (135)

Ref.

Ref.

92 (42)

Ref.

Ref.

Mutant-like

173 (67)

2.87 (1.74–4.71)

2.24 (1.35–3.70)

93 (38)

2.94 (1.50–5.74)

2.03 (1.03–4.03)

80 (29)

1.34 (0.62–2.94)

1.41 (0.64–3.11)

Tc

 

0.88 (0.81–0.95)

0.88 (0.81–0.96)

 

0.91 (0.82–1.00)

0.91 (0.83–1.01)

 

0.88 (0.74–1.04)

0.88 (0.74–1.04)

PAM50 subtype

Other

1,127 (356)

Ref.

Ref.

992 (287)

Ref.

Ref.

124 (67)

Ref.

Ref.

Basal-like

213 (84)

3.91 (2.57–5.96)

3.43 (2.23–5.26)

31 (14)

3.43 (1.27–9.24)

3.28 (1.22–8.79)

179 (69)

0.99 (0.59–1.66)

1.13 (0.66–1.93)

Tc

 

0.83 (0.76–0.89)

0.82 (0.76–0.88)

 

0.91 (0.78–1.06)

0.91 (0.78–1.06)

 

0.91 (0.82–1.00)

0.90 (0.81–0.99)

  1. ER estrogen receptor, IHC immunohistochemistry, METABRIC Molecular Taxonomy of Breast Cancer International Consortium, PAM50 Prediction Analysis of Microarray 50.
  2. aAdjusted for age at diagnosis (continuous).
  3. bAdditionally adjusted for tumor stage, grade, size, and node status.
  4. cLog of time-varying coefficient (if T < 1 then hazard decreases with time, and if T > 1 then hazard increases with time).
Back to article page